{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:04:37Z","timestamp":1765609477515,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.amjmed.2011.03.013","type":"journal-article","created":{"date-parts":[[2011,7,12]],"date-time":"2011-07-12T20:02:16Z","timestamp":1310500936000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions"],"prefix":"10.1016","volume":"124","author":[{"given":"Raffaele","family":"De Caterina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2011.03.013_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.03.013_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2011.03.013_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.STR.27.10.1765","article-title":"Acute stroke with atrial fibrillation","volume":"27","author":"Jorgensen","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2011.03.013_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH07-08-0508","article-title":"Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data","volume":"99","author":"Hughes","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2011.03.013_bib5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehl492","article-title":"Anticoagulants in heart disease: current status and perspectives","volume":"28","author":"De Caterina","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.03.013_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2011.03.013_bib7","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2011.03.013_bib8","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2011.03.013_bib9","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.03.013_bib10","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2011.03.013_bib11","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.03.013_bib12","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2011.03.013_bib13","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/eurheartj\/ehp318","article-title":"Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists","volume":"30","author":"Lip","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.03.013_bib14","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/circ.114.4.257","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"issue":"6 Suppl","key":"10.1016\/j.amjmed.2011.03.013_bib15","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2011.03.013_bib16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/STROKEAHA.107.501825","article-title":"Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation","volume":"39","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2011.03.013_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2011.03.013_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2011.03.013_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin vs aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2011.03.013_bib20","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/STROKEAHA.107.500199","article-title":"Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)","volume":"39","author":"Healey","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2011.03.013_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1540-8167.2009.01661.x","article-title":"The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1","volume":"21","author":"Lee","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjmed.2011.03.013_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1160\/TH09-10-0746","article-title":"Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1","volume":"103","author":"Gorin","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2011.03.013_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jacc.2005.06.077","article-title":"Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation","volume":"46","author":"Waldo","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2011.03.013_bib24","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"issue":"Abs 4634","key":"10.1016\/j.amjmed.2011.03.013_bib25","first-page":"S923","article-title":"Profile of patients according to chosen therapeutic strategy in the RecordAF global registry on atrial fibrillation management","volume":"118","author":"Le Heuzey","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2011.03.013_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.03.013_bib27","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0735-1097(03)00416-9","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"41","author":"Hirsh","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"6 Suppl","key":"10.1016\/j.amjmed.2011.03.013_bib28","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2011.03.013_bib29","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1093\/eurheartj\/sui031","article-title":"Reviewing the reality: why we need to change","author":"Lin","year":"2005","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.amjmed.2011.03.013_bib30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2125.2004.02086.x","article-title":"Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management","volume":"57","author":"Deplanque","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjmed.2011.03.013_bib31","first-page":"165","article-title":"Use of anticoagulants in elderly patients: practical recommendations","volume":"4","author":"Robert-Ebadi","year":"2009","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.amjmed.2011.03.013_bib32","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/eurheartj\/ehl146","article-title":"Stroke prophylaxis in atrial fibrillation: who gets it and who does not?","volume":"27","author":"Friberg","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.03.013_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCOUTCOMES.109.884171","article-title":"Cognitive function and anticoagulation control in patients with atrial fibrillation","volume":"3","author":"Flaker","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjmed.2011.03.013_bib34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2459\/JCM.0b013e32832e496b","article-title":"What can ongoing clinical trials of anticoagulants demonstrate?","volume":"10","author":"Halperin","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.amjmed.2011.03.013_bib35","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2147\/VHRM.S3266","article-title":"Emergence of new oral antithrombotics: a critical appraisal of their clinical potential","volume":"4","author":"Lassen","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.amjmed.2011.03.013_bib36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2011.03.013_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2011.03.013_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000091265","article-title":"Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation","volume":"21","author":"Diener","year":"2006","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.amjmed.2011.03.013_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.amjmed.2011.03.013_bib41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran vs warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.03.013_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.03.013_bib43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.109.856120","article-title":"The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation","volume":"120","author":"Ellis","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2011.03.013_bib44","doi-asserted-by":"crossref","first-page":"348 e1","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban vs acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","author":"Eikelboom","year":"2010","journal-title":"Am Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431100252X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293431100252X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:56:18Z","timestamp":1757580978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293431100252X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S000293431100252X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.03.013","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}